Immunome
IMNM
120 hedge funds and large institutions have $566M invested in Immunome in 2024 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 38 increasing their positions, 35 reducing their positions, and 27 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
22% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 27
4% more funds holding
Funds holding: 115 → 120 (+5)
9% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 35
0.57% less ownership
Funds ownership: 85.98% → 85.41% (-0.57%)
25% less capital invested
Capital invested by funds: $755M → $566M (-$188M)
98% less call options, than puts
Call options by funds: $439K | Put options by funds: $21.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$9.7M |
| 2 |
JP Morgan Chase
New York
|
+$7.54M |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$3.8M |
| 4 |
Renaissance Technologies
New York
|
+$3.68M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$12.8M |
| 2 |
Brown Advisory
Baltimore,
Maryland
|
-$12.6M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$10.7M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
-$10.5M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$6.58M |
IMNM Hedge Fund Activity: Q4 2024 in Review
120 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Immunome (IMNM) for Q4 2024, worth a combined $566M — down 25% from $755M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new IMNM positions and 27 closed out — a net gain of 6 holders — while 38 added to existing stakes and 35 trimmed.
The largest buyer was Opaleye Management, adding an estimated $9.7M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $12.8M sold.
- 120 institutional investors held Immunome (IMNM) as of Q4 2024, up from 115 in Q3 2024.
- Funds reported $566M of Immunome stock for Q4 2024, down 25% quarter-over-quarter.
- 33 funds opened new Immunome positions in Q4 2024 and 27 closed out, a net change of +6 holders.
- The largest Immunome buyer in Q4 2024 was Opaleye Management, an estimated $9.7M added.
- The largest Immunome seller in Q4 2024 was Avidity Partners Management, an estimated $12.8M sold.
Based on aggregated 13F filings for Q4 2024.